Fewer collection trips as Valencia’s diabetes deliveries reach nearly 70%

That is a substantial practical change. It is also an unfinished rollout: the Generalitat has not given a date for reaching the remaining users, or published results showing how reliably repeat supplies arrive. Its figures measure how many people deliveries have reached, not whether every subsequent delivery has arrived when needed.⁠2

The regional total covers 14,985 monitoring users in Valencia province, 10,897 in Alicante and 2,568 in Castellón. Those are counts of people using monitoring systems—not provincial totals of home-delivery recipients, and not counts of everyone with diabetes. Because the delivery percentage is approximate, it cannot yield an exact number of recipients.⁠2

The Home Delivery program sends glucose-monitoring sensors and consumables used with continuous insulin-infusion systems, or pumps. That does not mean the announcement covers delivery of insulin itself, or that every person using a glucose sensor also uses a pump. The immediate change is where patients obtain the specified material: at home rather than through a collection trip.⁠1

Regional Secretary for Health Asunción Perales described the progress at the fourth AVDiabetes meeting, organized by the Asociación Valenciana de Diabetes for World Diabetes Day at Hospital General Universitario de València. She said the initiative was intended to make daily treatment products and devices easier to obtain, improve continuity of care and reduce journeys to collect supplies. Greater autonomy, comfort and quality of life are its stated objectives; the update does not measure those benefits.⁠2

November’s announcement is a progress report, not the launch of a new service. The rollout began on June 9, 2026, with patients joining progressively, starting with users of the most widely deployed monitoring devices. The launch plan envisaged extending deliveries to the other systems included in the program. Around 27,000 people were using monitoring systems in the public health service at that point; that approximate figure was not a count of people already receiving packages.⁠7

At the launch, Regional Health Minister Marciano Gómez singled out children, people with mobility difficulties and patients living far from health facilities as groups for whom easier access mattered. He also emphasized reducing administrative burdens on patients, families and professionals. For those households, the value of home delivery is straightforward: an ongoing treatment requirement need not generate a recurring collection journey. The available update does not quantify their travel costs or time saved.⁠7⁠2

Other Spanish regions already had home-shipping programs for glucose sensors. The Valencian model’s stated distinguishing feature was coordination from within the public health system, linking prescribing, patient enrollment, logistics and clinical follow-up through the health department’s own systems and removing paper documentation from that process. Logistics providers still handle deliveries; public coordination does not mean the health service performs every part of the journey itself.⁠7

Implementation was to be coordinated in each health department by multidisciplinary groups bringing together primary care, endocrinology, nursing, primary-care pharmacy, information technology and supplies staff. The design included secure communication with logistics providers and round-the-clock patient-provider channels for delivery questions or incidents. Clinicians were to work through their usual clinical systems without opening each supplier’s separate platform.⁠7

Those arrangements matter because a delivery service is only as useful as its ability to keep supplying what a patient needs. An incident channel and a coordinated ordering process are sensible infrastructure, but their existence is not evidence of on-time performance. The November figures do not establish delivery frequency, uninterrupted supply or how quickly problems are resolved.⁠7⁠2

The service was designed to include education in using the devices and continuing professional follow-up. A parcel is not a substitute for diabetes care. At launch, officials described clinicians having access to reports compiling patients’ glucose-control data from home, intended to support more personalized, proactive monitoring and earlier identification of problems. These were clinical aims, not measured outcomes accompanying the delivery figures.⁠7

Perales described a further technical development in November: integrating sensor information into patients’ electronic health records so professionals could assess glucose levels and their evolution over time. The earlier availability of glucose reports does not by itself establish that this integration is complete. The update gives neither a completion date nor a region-wide implementation figure for that work.⁠2

The financial picture also needs a careful reading. The June launch account described annual investment exceeding €38 million in glucose-control devices and consumables, alongside incorporation of the digital home-distribution system. That is not a separately itemized shipping budget, a demonstrated saving or a new November allocation. The available breakdown does not isolate the cost of home delivery itself.⁠7

The clearest achievement is therefore practical rather than clinical: many monitoring users have obtained essential supplies without travelling to collect them. Nothing in the announcement establishes that people not yet recorded as home-delivery recipients have lost access to supplies. What remains missing is a timetable for extending that convenience to the rest, and evidence that it continues reliably after the first delivery.⁠2

For a service supporting ongoing treatment, reaching a household is the beginning of the job. Keeping it supplied is the standard that will ultimately matter.